Clinical Stage Drug Discovery Based on Our Proprietary Platform Technology

SMNH: Delivering Novel Chemistry Solutions for Today's Diseases

SB 9200: A Potential Breakthrough Drug for HBV

Latest News

    • 31 OCT 16

    Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2016 Financial Results

    Reaffirms on track to report initial results from the first dosing cohort in ACHIEVE Phase 2 chronic Hepatitis B trial of SB9200 during the first half of 2017
    HOPKINTON, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced third quarter 2016 financial results and provided an update on recent corporate and clinical developments.

    “We made steady progress in the third quarter of 2016, as we continued to enroll patients in our ACHIEVE Phase 2 clinical trial involving our lead compound, SB 9200,…

    Read more →